Abstract: The present invention belonging to the technical field of biopharmaceutical discloses bifunctional molecules which are used to recruit antibodies and target tumor cells. The bifunctional molecules in the present invention comprise at least one recruitment moiety capable of binding to the existing antibodies in the body and a targeting moiety capable of selectively binding to the tumor cell. The compounds according to the invention selectively bind to the surface of the cancer cells, and recruit the existing antibodies through the recruitment moiety, and mediate the humoral and cellular immune responses to the cancer cell in the patient. According to this physiological function of the compounds according to the invention, cancer cells can be immunoregulated, which provides a new strategy for tumor immunotherapy.

Abstract: Antibody conjugates with enhanced immune effector functions of antibody, are disclosed herein. The antibody conjugates are obtained by modifying the antibody with at least a hapten derivative. The hapten derivative consists of a hapten, a linker, and a coupling domain. Through a mild and simple method, the hapten derivative is conjugated to the antibody, resulting in an antibody conjugate that not only retains the excellent affinity of the original antibody but also recruits specific natural antibodies to target tumor cells. This antibody conjugate has enhanced immune effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Importantly, the present invention optimizes the length of the linker and develops SMCC-PEG3-Rha as the hapten derivative. Compared to other reported antibodies, the antibody conjugate modified with SMCC-PEG3-Rha exhibits more prominent immune effector functions.

Abstract: The present invention belonging to the technical field of biopharmaceutical discloses bifunctional molecules which are used to recruit antibodies and target tumor cells. The bifunctional molecules in the present invention comprise at least one recruitment moiety capable of binding to the existing antibodies in the body and a targeting moiety capable of selectively binding to the tumor cell. The compounds according to the invention selectively bind to the surface of the cancer cells, and recruit the existing antibodies through the recruitment moiety, and mediate the humoral and cellular immune responses to the cancer cell in the patient. According to this physiological function of the compounds according to the invention, cancer cells can be immunoregulated, which provides a new strategy for tumor immunotherapy.